Compare Stocks: COYA, EPRX, LRMR, and OCGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COYA Coya Therapeutics	$4.80 +3.4%	$4.86	$3.71 ▼ $7.75	$108.84M	0.6	207,352 shs	130,175 shs
EPRX Eupraxia Pharmaceuticals	$6.70 +0.6%	$6.40	$5.04 ▼ $9.32	$433.03M	1.08	370,300 shs	181,022 shs
LRMR Larimar Therapeutics	$4.31 +7.5%	$3.67	$2.71 ▼ $6.42	$416.57M	0.81	1.27 million shs	1.66 million shs
OCGN Ocugen	$1.37 +4.6%	$1.34	$0.98 ▼ $2.73	$444.23M	2.21	4.76 million shs	2.46 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COYA Coya Therapeutics	+3.45%	+5.03%	-8.75%	+5.73%	-21.95%
EPRX Eupraxia Pharmaceuticals	+0.60%	+2.76%	+0.30%	-11.26%	+25.94%
LRMR Larimar Therapeutics	+7.48%	+4.87%	+0.70%	+5.12%	+14.02%
OCGN Ocugen	+4.58%	+4.58%	-6.80%	-6.80%	+39.70%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COYA Coya Therapeutics	$4.80 +3.4%	$4.86	$3.71 ▼ $7.75	$108.84M	0.6	207,352 shs	130,175 shs
EPRX Eupraxia Pharmaceuticals	$6.70 +0.6%	$6.40	$5.04 ▼ $9.32	$433.03M	1.08	370,300 shs	181,022 shs
LRMR Larimar Therapeutics	$4.31 +7.5%	$3.67	$2.71 ▼ $6.42	$416.57M	0.81	1.27 million shs	1.66 million shs
OCGN Ocugen	$1.37 +4.6%	$1.34	$0.98 ▼ $2.73	$444.23M	2.21	4.76 million shs	2.46 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COYA Coya Therapeutics	+3.45%	+5.03%	-8.75%	+5.73%	-21.95%
EPRX Eupraxia Pharmaceuticals	+0.60%	+2.76%	+0.30%	-11.26%	+25.94%
LRMR Larimar Therapeutics	+7.48%	+4.87%	+0.70%	+5.12%	+14.02%
OCGN Ocugen	+4.58%	+4.58%	-6.80%	-6.80%	+39.70%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COYA Coya Therapeutics	2.71	Moderate Buy	$15.33	219.44% Upside
EPRX Eupraxia Pharmaceuticals	2.89	Moderate Buy	$18.00	168.66% Upside
LRMR Larimar Therapeutics	3.09	Buy	$12.57	191.68% Upside
OCGN Ocugen	2.60	Moderate Buy	$9.50	593.43% Upside

Current Analyst Ratings Breakdown

Latest COYA, EPRX, LRMR, and OCGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/5/2026	LRMR Larimar Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$12.00 ➝ $11.00
7/17/2026	COYA Coya Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	EPRX Eupraxia Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	LRMR Larimar Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	EPRX Eupraxia Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
7/2/2026	LRMR Larimar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00
6/30/2026	LRMR Larimar Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/30/2026	LRMR Larimar Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$7.00 ➝ $5.00
6/25/2026	EPRX Eupraxia Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$17.00
6/23/2026	OCGN Ocugen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/12/2026	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$14.00

(Data available from 8/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COYA Coya Therapeutics	$7.95M	14.16	N/A	N/A	$2.06 per share	2.33
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	$1.41 per share	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$1.23 per share	N/A
OCGN Ocugen	$4.41M	105.35	N/A	N/A	($0.05) per share	-27.40

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COYA Coya Therapeutics	-$21.23M	-$1.15	N/A	N/A	N/A	-266.10%	-55.86%	-48.86%	N/A
EPRX Eupraxia Pharmaceuticals	-$38.58M	-$1.05	N/A	N/A	N/A	N/A	-87.56%	-51.20%	N/A
LRMR Larimar Therapeutics	-$165.67M	-$1.95	N/A	N/A	N/A	N/A	-137.39%	-97.65%	8/13/2026 (Estimated)
OCGN Ocugen	-$67.85M	-$0.26	N/A	N/A	N/A	N/A	-127,987.80%	-115.95%	N/A

Latest COYA, EPRX, LRMR, and OCGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	LRMR Larimar Therapeutics	-$0.39	N/A	N/A	N/A	N/A	N/A
8/11/2026	Q2 2026	COYA Coya Therapeutics	-$0.3457	-$0.28	+$0.0657	-$0.28	$0.13 million	$0.22 million
8/11/2026	Q2 2026	EPRX Eupraxia Pharmaceuticals	-$0.25	-$0.23	+$0.02	-$0.23	N/A	N/A
8/6/2026	Q2 2026	OCGN Ocugen	-$0.0533	-$0.07	-$0.0167	-$0.07	$0.89 million	$1.49 million
8/4/2026	Q2 2026	LRMR Larimar Therapeutics	-$0.3815	-$0.30	+$0.0815	-$0.30	N/A	N/A
5/14/2026	Q1 2026	LRMR Larimar Therapeutics	-$0.53	-$0.31	+$0.22	-$0.31	N/A	N/A
5/12/2026	Q1 2026	COYA Coya Therapeutics	-$0.39	-$0.32	+$0.07	-$0.32	$0.15 million	$0.25 million
5/12/2026	Q1 2026	EPRX Eupraxia Pharmaceuticals	-$0.22	-$0.23	-$0.01	-$0.23	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A
OCGN Ocugen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COYA Coya Therapeutics	N/A	15.02	15.02
EPRX Eupraxia Pharmaceuticals	0.02	19.31	19.31
LRMR Larimar Therapeutics	N/A	4.70	4.70
OCGN Ocugen	4.17	0.80	0.80

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COYA Coya Therapeutics	39.75%
EPRX Eupraxia Pharmaceuticals	N/A
LRMR Larimar Therapeutics	91.92%
OCGN Ocugen	10.27%

Insider Ownership

Company	Insider Ownership
COYA Coya Therapeutics	6.10%
EPRX Eupraxia Pharmaceuticals	N/A
LRMR Larimar Therapeutics	4.00%
OCGN Ocugen	3.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COYA Coya Therapeutics	6	23.46 million	22.03 million	Not Optionable
EPRX Eupraxia Pharmaceuticals	29	65.02 million	N/A	N/A
LRMR Larimar Therapeutics	30	103.88 million	99.73 million	Optionable
OCGN Ocugen	80	339.11 million	325.72 million	Optionable

COYA, EPRX, LRMR, and OCGN Headlines

Recent News About These Companies

Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX) and Ocugen (OCGN)

August 11 at 3:27 PM | theglobeandmail.com

Research Analysts Issue Forecasts for Ocugen Q3 Earnings

August 11 at 7:42 AM | marketbeat.com

What is Noble Financial's Forecast for Ocugen Q3 Earnings?

August 11 at 7:42 AM | marketbeat.com

Hennion & Walsh Asset Management Inc. Purchases 1,553,672 Shares of Ocugen, Inc. $OCGN

August 10 at 5:27 AM | marketbeat.com

Ocugen (OCGN) Receives a Buy from Noble Financial

August 8, 2026 | theglobeandmail.com

Ocugen (NASDAQ:OCGN) Downgraded by Wall Street Zen to "Sell"

August 8, 2026 | marketbeat.com

Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls

August 7, 2026 | finance.yahoo.com

Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls

August 7, 2026 | zacks.com

Ocugen targets 3 BLAs by 2028 as FDA clears OCU410 Phase III and cash runway extends into 2028

August 7, 2026 | seekingalpha.com

Ocugen: Q2 Earnings Snapshot

August 7, 2026 | aol.comA

Ocugen Q2 Earnings Call Highlights

August 7, 2026 | marketbeat.com

Ocugen (NASDAQ:OCGN) Posts Earnings Results, Misses Estimates By $0.02 EPS

August 6, 2026 | marketbeat.com

Ocugen Inc (OCGN) (Q2 2026) Earnings Call Highlights: FDA Clearance for OCU410 Phase 3 Trial ...

August 6, 2026 | finance.yahoo.com

Ocugen (OCGN) Reports Q2 Loss, Beats Revenue Estimates

August 6, 2026 | finance.yahoo.com

Ocugen (OCGN) Reports Q2 Loss, Beats Revenue Estimates

August 6, 2026 | zacks.com

Ocugen Reports Q2 2026 Results, Advances OCU410 Phase 3, Secures RMAT Designation and $130 Million Financing

August 6, 2026 | quiverquant.comQ

Ocugen Provides Business Update with Second Quarter 2026 Financial Results

August 6, 2026 | globenewswire.com

Ocugen to Participate in Upcoming August Investor Conferences

July 31, 2026 | finance.yahoo.com

Ocugen to Present Modifier Gene Therapy Platform at Upcoming August 2026 Investor Conferences

July 31, 2026 | quiverquant.comQ

Ocugen to Participate in Upcoming August Investor Conferences

July 31, 2026 | globenewswire.com

Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy ...

July 29, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

COYA, EPRX, LRMR, and OCGN Company Descriptions

Coya Therapeutics NASDAQ:COYA

$4.80 +0.16 (+3.45%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$4.82 +0.02 (+0.48%)

As of 08/11/2026 07:57 PM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Eupraxia Pharmaceuticals NASDAQ:EPRX

$6.70 +0.04 (+0.60%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$6.72 +0.01 (+0.22%)

As of 08/11/2026 04:10 PM Eastern

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

Larimar Therapeutics NASDAQ:LRMR

$4.31 +0.30 (+7.48%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$4.32 +0.01 (+0.12%)

As of 08/11/2026 07:34 PM Eastern

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Ocugen NASDAQ:OCGN

$1.37 +0.06 (+4.58%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$1.36 -0.01 (-0.66%)

As of 08/11/2026 07:59 PM Eastern

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest COYA, EPRX, LRMR, and OCGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest COYA, EPRX, LRMR, and OCGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

COYA, EPRX, LRMR, and OCGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

COYA, EPRX, LRMR, and OCGN Company Descriptions

Coya Therapeutics NASDAQ:COYA

Eupraxia Pharmaceuticals NASDAQ:EPRX

Larimar Therapeutics NASDAQ:LRMR

Ocugen NASDAQ:OCGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest COYA, EPRX, LRMR, and OCGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest COYA, EPRX, LRMR, and OCGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

COYA, EPRX, LRMR, and OCGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

COYA, EPRX, LRMR, and OCGN Company Descriptions

Coya Therapeutics NASDAQ:COYA

Eupraxia Pharmaceuticals NASDAQ:EPRX

Larimar Therapeutics NASDAQ:LRMR

Ocugen NASDAQ:OCGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools